Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities

Journal of Asthma

Volumn 51, Issue 1, 2014, Pages 1-17

  Pacheco, Yves ^a   Freymond, Nathalie ^a   Devouassoux, Gilles ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CROIX ROUSSE HOSPITAL   (France)

Author keywords

Aspirin; Asthma; Exercise; Leukotriene; Montelukast; Overweight; Rhinitis; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO;

ASTHMA; COMORBIDITY; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIVITY; EXERCISE INDUCED ASTHMA; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LONG TERM CARE; MONOTHERAPY; OBESITY; REVIEW; RHINITIS; RHINITIS ASSOCIATED ASTHMA; SIGNAL TRANSDUCTION; SMOKING; THERAPY; TOBACCO; TREATMENT RESPONSE;

ACETATES; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; COMORBIDITY; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; RHINITIS;

EID: 84893145179     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.822081     Document Type: Review

References (105)

1. Basagana X, Sunyer J, Kogevinas M, Zock JP, Duran-Tauleria E, Jarvis D, Burney P, Anto JM; European Community Respiratory Health Survey. Socioeconomic status and asthma prevalence in young adults: The European Community Respiratory Health Survey. Am J Epidemiol 2004;160:178-188
2. Afrite A, Allonier C, Com-Ruelle L, Le Guen N, Annesi-Maesano I, Delmas M-C, Furhman C, Leynaert B. Asthma in France in 2006: Prevalence and control of symptoms. In: Ed Yann Bourgueil, ed. Issues in health economics No 138. Paris: Institute for Research and Information in health Economics (IRDES); 2008:1-8
3. Varghese M, Lockey RF. Aspirin-exacerbated asthma. Allergy Asthma Clin Immunol 2008;4:75-83
4. GINA Report, Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Updated 2011. Available from: Http://www.ginasthma.com/GuidelinesResources. asp [last accessed 5 June 2012
5. Lima JJ. Treatment heterogeneity in asthma: Genetics of response to leukotriene modifiers. Mol Diagn Ther 2007;11:97-104
6. Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: Clinical implications. Curr Opin Pulm Med 2010;16:13-18
7. Hallstrand TS, Henderson Jr. WR. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010;10: 60-66
8. Magnan A, Vervloet D. Anti-leucotrienes (2): Place of antileucotrienes in asthma and rhinitis pathophysiology. Rev Fr Allergol 1999;39:25-29 [French
9. Giouleka P, Papatheodorou G, Lyberopoulos P, Karakatsani A, Alchanatis M, Roussos C, Papiris S, Loukides S. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest 2011;41:30-38
10. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008;121: 1365-1371
11. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, et al Childhood Asthma Research and Education Network of the National Heart, Lung, Blood Institute. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003;112:883-892
12. Gogate S, Katial R. Pediatric biomarkers in asthma: Exhaled nitric oxide, sputum eosinophils and leukotriene E4. Curr Opin Allergy Clin Immunol 2008;8:154-157
13. Blake KV. Montelukast: Data from clinical trials in the management of asthma. Ann Pharmacother 1999;33:1299-1314
14. Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: Multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689-703
15. Merck & Co USA. Singulair- full prescribing information. Revised 03/2012. USPI-MF-04761203R023. Available from: Http:// www.merck.com/product/ usa/pi-circulars/s/singulair/singulair-pi. pdf [last accessed 5 June 2012
16. ANSM. Summary of Product Characteristics Singulair-. Updated 19/10/2011. [French] Available from: Http://agence-prd.ansm. sante.fr/php/ecodex/frames.php? specid69863646&typedocR& refR0200028.htm [last accessed 5 June 2012
17. Medicine Compendium UK. Summary of Product Characteristics Singulair-. Last updated on 22/08/2011. Available from: Http:// www.medicines.org.uk/emc/ medicine/17718/SPC/#INDICATIONS [last accessed 5 June 2012
18. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: A systematic review and metaanalysis. Am J Med 2004;116:338-344
19. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: An evidence-based review. Drugs 2007;67:887-901
20. Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther 2009;26:575-587
21. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, et al Global Allergy and Asthma European Network;Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-476
22. Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, Grant E, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96: 60-68
23. Baena-Cagnani CE, Berger WE, DuBuske LM, Gurné SE, Stryszak P, Lorber R, Danzig M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-Agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307-313
24. Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma 2009;46:413-420
25. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100: 1952-1959
26. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005; 128:1910-1920
27. Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc 2010; 31:68-75
28. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, Reiss TF. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549-1558
29. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, et al Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58: 211-216
30. Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: Analysis from the COMPACT trial. Allergy 2006;61: 737-742
31. Borderias L, Mincewicz G, Paggiaro PL, Guilera M, Sazonov Kocevar V, Taylor SD, Badia X. Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: A retrospective observational study. Curr Med Res Opin 2007;23:721-730
32. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-Acting beta-2-Agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16:17A-31A
33. Korn D, Van den Brande P, Potvin E, Dramaix M, Herbots E, Peché R. Efficacy of add-on montelukast in patients with non-controlled asthma: A Belgian open-label study. Curr Med Res Opin 2009;25: 489-497
34. Zhang Q, Thomas M, Wisniewski T, Sazonov Kocevar V, Price D. Treatment and outcomes in patients with asthma and allergic rhinitis in the United kingdom. Int Arch Allergy Immunol 2007; 142:318-328
35. Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62:73-80
36. Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger ''real life'' population of patients with obstructive lung disease? Respir Med 2005;99:11-19
37. de Benedictis FM, Vaccher S, de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc) 2008;44: 845-855
38. McFadden Jr. ER, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330:1362-1367
39. Kemp JP. Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist. Ther Clin Risk Manag 2009;5:923-933
40. Grzelewski T, Stelmach I. Exercise-induced bronchoconstriction in asthmatic children: A comparative systematic review of the available treatment options. Drugs 2009;69:1533-1553
41. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Doserelated protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556-561
42. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-152
43. Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-Tolerant patients with asthma. Clin Exp Allergy 2002;32:1360-1365
44. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006;97:98-104
45. Philip G, Villarán C, Pearlman DS, Loeys T, Dass SB, Reiss TF. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007;44:213-217
46. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exerciseinduced bronchoconstriction in 6-To 14-year-old children with asthma. J Pediatr 1998;133:424-428
47. Melo RE, Solé D, Naspitz CK. Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003;111:301-307
48. Kim JH, Lee SY, Kim HB, Kim BS, Shim JY, Hong TJ, Hong SJ. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 2005;39: 162-166
49. Peroni DG, Piacentini GL, Ress M, Bodini A, Loiacono A, Aralla R, Boner AL. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002;13:434-437
50. de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006;28:291-295
51. Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, Piacentini GL. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med 2011;105: 1790-1797
52. Wasfi YS, Kemp JP, Villarán C, Massaad R, Xin W, Smugar SS, Knorr BA, Philip G. Onset and duration of attenuation of exerciseinduced bronchoconstriction in children by single-dose of montelukast. Allergy Asthma Proc 2011;32:453-459
53. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia-Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol 2006;41:222-227
54. Raissy HH, Harkins M, Kelly F, Kelly HW. Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. Pharmacotherapy 2008;28:287-294
55. Lecheler J, Pfannebecker B, Nguyen DT, Petzold U, Munzel U, Kremer HJ, Maus J. Prevention of exercise-induced asthma by a fixed combination of disodium cromoglycate plus reproterol compared with montelukast in young patients. Arzneimittelforschung 2008;58:303-309
56. Philip G, Pearlman DS, Villarán C, Legrand C, Loeys T, Langdon RB, Reiss TF. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 2007;132: 875-883
57. Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, Langley SJ, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999;104:547-553
58. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000;132:97-104
59. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004;98: 1051-1062
60. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-368
61. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-Agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002;165:1068-1070
62. Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, Smugar SS, Polos PG. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010;104:511-517
63. Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2001;86:655-658
64. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008;121:383-389
65. Carver TW. Exercise-induced asthma: Critical analysis of the protective role of montelukast. J Asthma Allergy 2009;2:93-103
66. National Institutes of Health. Expert Panel Report 3. Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. Bethesda, MD: National Institutes of Health; 2007
67. Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH. Smoking and asthma. J Am Board Fam Med 2011;24:313-322
68. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-230
69. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-1311
70. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005;60:282-287
71. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, et al National Heart Lung and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783-790
72. Montelukast Asthmatic Smoker Study, identifier: NCT00712335, ClinicalTrials.gov (2006). Available from: Http://www.clinicaltrials. gov/ct2/show/NCT00712335?intr%22Montelukast%22& rank39 [last accessed 5 June 2012
73. Sutherland ER. Obesity and asthma. Immunol Allergy Clin North Am 2008;28:589-602
74. Stream AR, Sutherland ER. Obesity and asthma disease phenotypes. Curr Opin Allergy Clin Immunol 2012;12:76-81
75. Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, Lima JJ, et al; American Lung Association-Asthma Clinical Research Centers. Effect of obesity on clinical presentation and response to treatment in asthma. J Asthma 2006; 43:553-558
76. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007;101:2240-2247
77. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008;178:682-687
78. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006;27:495-503
79. Sutherland ER, Camargo Jr. CA, Busse WW, Meltzer EO, Ortega HG, Yancey SW, Emmett AH, Stempel DA. Comparative effect of body mass index on response to asthma controller therapy. Allergy Asthma Proc 2010;31:20-25
80. Camargo Jr. CA, Boulet LP, Sutherland ER, Busse WW, Yancey SW, Emmett AH, Ortega HG, Ferro TJ. Body mass index and response to asthma therapy: Fluticasone propionate/salmeterol versus montelukast. J Asthma 2010;47:76-82
81. O'Byrne PM, Gauvreau GM, Murphy DM. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. J Allergy Clin Immunol 2009;124:397-403
82. Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006;6:198-202
83. Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14
84. Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, Bestynska-Krypel A, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949-955
85. Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-Aspirin challenge in patients with aspirininduced asthma. Eur Respir J 2004;24:226-230
86. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, DaI Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: A controlled study vs placebo. Allergy 2004;59:289-294
87. Schäper C, Noga O, Koch B, Ewert R, Felix SB, Gläser S, Kunkel G, Gustavus B. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011;21: 51-58
88. Paganin F, Poubeau P, Yvin JL, Arvin-Berod C. [The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. Presse Med 2003;32:978-984
89. Park JS, Jang AS, Park SW, Lee YM, Uh ST, Kim YH, Cha JY, et al. Protection of leukotriene receptor antagonist against aspirininduced bronchospasm in asthmatics. Allergy Asthma Immunol Res 2010;2:48-54
90. Pasaje CF, Kim JH, Park BL, Cheong HS, Park TJ, Lee JS, Kim Y, et al. Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients. Pulm Pharmacol Ther 2011;24:595-601
91. Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY, Park HS. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics 2007;8:1143-1150
92. Kim JH, Lee SY, Kim HB, Jin HS, Yu JH, Kim BJ, Kim BS, et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy 2008;38:51-59. Erratum in: Clin Exp Allergy 2008;38:383
93. Haute Autorité de santé (HAS). Avis de la commission. Singulair 5 et 10mg (comprimé à croquer). Examen du dossier des spécialités inscrites pour une durée de 5 ans par arrêté du 30 décembre 1999 (JO du 1er janvier 2000). Commission de la Transparence, 2005:1-11
94. Farid-Moayer M, Lowe ST. Churg-Strauss Syndrome. Available from: Http://emedicine.medscape.com/article/333492-overview [last accessed 31 Jul 2009
95. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691e6-696e6
96. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124: 699e8-706e8
97. Qin P, Mortensen PB, Waltoft BL, Postolache TT. Allergy is associated with suicide completion with a possible mediating role of mood disorder-A population-based study. Allergy 2011;66: 658-664
98. Postolache TT, Komarow H, Tonelli LH. Allergy: A risk factor for suicide? Curr Treat Options Neurol 2008;10:363-376
99. Kelsay K. Assessing risk: Data from montelukast clinical trials. J Allergy Clin Immunol 2009;124:697-698
100. Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L, Alonso-Lebrero E. Neuropsychiatric Reactions to Montelukast. J Investig Allergol Clin Immunol 2012;22:437-459
101. Storms W, Michele TM, Knorr B, Nooman G, Shapiro G, Zhang J, Shingo S, Reiss TF. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients5/ 6 years. Clin Exp Allergy 2001;31:77-87
102. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Nooman G. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:5685-79
103. Ciebiada M, Ciebiada MG, Kmiecik T, DuBuske LM, Gorski P. Quality of Life in Patients With Persistent Allergic Rhinitis Treated With Montelukast Alone or in Combination With Levocetirizine or Desloratadine. J Invest Allergol Clin Immunol 2008;18:343-349
104. Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther 2008;30: 1026-1035
105. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske Jr. RF, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355-360